McKinnon, C., Nandhabalan, M., Murray, S. A. & Plaha, P. Glioblastoma: Scientific presentation, analysis, and administration. BMJ 374, n1560 (2021).
Schaff, L. R. & Mellinghoff, I. Ok. Glioblastoma and different major mind malignancies in adults: A evaluation. JAMA 329, 574–587 (2023).
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A abstract. Neuro Oncol. 23, 1231–1251 (2021).
Horbinski, C., Berger, T., Packer, R. J. & Wen, P. Y. Scientific implications of the 2021 version of the WHO classification of central nervous system tumours. Nat. Rev. Neurol. 18, 515–529 (2022).
Goto, A. et al. Diabetes and most cancers danger: A Mendelian randomization examine. Int. J. Most cancers 146, 712–719 (2020).
Wang, A. P. A evaluation of glioblastoma and different major mind malignancies. JAMA 330, 188 (2023).
Alarcón, S., Niechi, I., Toledo, F., Sobrevia, L. & Quezada, C. Glioma development in diabesity. Mol. Features Med. 66, 62–70 (2019).
Suh, S. & Kim, Ok. W. Diabetes and most cancers: Most cancers needs to be screened in routine diabetes evaluation. Diabetes Metab. J. 43, 733–743 (2019).
Goyal, R., Singhal, M. & Jialal, I. Kind 2 Diabetes. In StatPearls [Internet] (eds Goyal, R. et al.) (StatPearls Publishing, 2023).
Schmandt, R. E., Iglesias, D. A., Co, N. N. & Lu, Ok. H. Understanding weight problems and endometrial most cancers danger: Alternatives for prevention. Am. J. Obstet. Gynecol. 205, 518–525 (2011).
Chen, Y. et al. Affiliation between kind 2 diabetes and danger of most cancers mortality: A pooled evaluation of over 771,000 people within the Asia cohort consortium. Diabetologia 60, 1022–1032 (2017).
Rey-Reñones, C., Baena-Díez, J. M., Aguilar-Palacio, I., Miquel, C. & Grau, M. Kind 2 Diabetes mellitus and most cancers: Epidemiology. Physiopathol. Prev. Biomed. 9, 1429 (2021).
Barami, Ok., Lyon, L. & Conell, C. Kind 2 diabetes mellitus and glioblastoma multiforme-assessing danger and survival: Outcomes of a big retrospective examine and systematic evaluation of the literature. World Neurosurg. 106, 300–307 (2017).
Zhao, L., Zheng, Z. & Huang, P. Diabetes mellitus and the chance of glioma: A meta-analysis. Oncotarget 7, 4483–4489 (2016).
Disney-Hogg, L. et al. Affect of obesity-related danger components within the aetiology of glioma. Br. J. Most cancers 118, 1020–1027 (2018).
Gong, Y. et al. ABO blood kind, diabetes and danger of gastrointestinal most cancers in northern China. World J. Gastroenterol. 18, 563–569 (2012).
Sanderson, E. et al. Mendelian randomization. Nat. Rev. Strategies Prim. 2, 6 (2022).
Titova, O. E., Michaëlsson, Ok. & Larsson, S. C. Sleep Length and Stroke. Stroke 51, 3279–3285 (2020).
Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complicated traits and illnesses. Nat. Genet. 50, 693–698 (2018).
Montemurro, N., Perrini, P. & Rapone, B. Scientific danger and total survival in sufferers with diabetes mellitus, hyperglycemia and glioblastoma multiforme. A evaluation of the present literature. Int. J. Environ. Res. Public Well being 17, 8501 (2020).
Welch, M. R. & Grommes, C. Retrospective evaluation of the consequences of steroid remedy and antidiabetic treatment on survival in diabetic glioblastoma sufferers. CNS Oncol. 2, 237–246 (2013).
Assessing the suitability of abstract knowledge for two-sample Mendelian randomization analyses utilizing MR-Egger regression: the position of the I2 statistic – PubMed. https://pubmed.ncbi.nlm.nih.gov/27616674/.
Mounier, N. & Kutalik, Z. Bias correction for inverse variance weighting Mendelian randomization. Genet. Epidemiol. 47, 314–331 (2023).
Hartley, A. E., Energy, G. M., Sanderson, E. & Smith, G. D. A information for understanding and designing Mendelian randomization research within the musculoskeletal discipline. JBMR Plus 6, e10675 (2022).
Grommes, C., Conway, D. S., Alshekhlee, A. & Barnholtz-Sloan, J. S. Inverse affiliation of PPARγ agonists use and excessive grade glioma improvement. J. Neurooncol. 100, 233–239 (2010).
For glioma, a candy aspect to diabetes | Neuro-Oncology | Oxford Tutorial. https://educational.oup.com/neuro-oncology/article/18/3/306/2509370.
Saewai, C., Fumaneeshoat, O., Thongsuksai, P. & Ingviya, T. Diabetes mellitus as most cancers danger: A 14-year cross-sectional evaluation. Nutr. Most cancers 75, 1454–1463 (2023).
Chen, Y. et al. Diabetes medicines and most cancers danger associations: A scientific evaluation and meta-analysis of proof over the previous 10 years. Sci. Rep. 13, 11844 (2023).
Dankner, R. et al. Time-dependent danger of most cancers after a diabetes analysis in a cohort of two.3 million adults. Am. J. Epidemiol. 183, 1098–1106 (2016).
Fontvieille, E. et al. Physique mass index and most cancers danger amongst adults with and with out cardiometabolic illnesses: Proof from the EPIC and UK Biobank potential cohort research. BMC Med. 21, 418 (2023).
Müller, D. M. J. et al. Evaluating glioblastoma surgical procedure selections between groups utilizing mind maps of tumor places, biopsies, and resections. JCO Clin. Most cancers Inform. 3, 1–12 (2019).
Chen, Y.-R. et al. The impact of postoperative an infection on survival in sufferers with glioblastoma. J. Neurosurg. 127, 807–811 (2017).
Seliger, C. et al. Use of metformin and consequence of sufferers with newly identified glioblastoma: Pooled evaluation. Int. J. Most cancers 146, 803–809 (2020).
Metformin influences development in diabetic glioblastoma sufferers | Strahlentherapie und Onkologie. https://hyperlink.springer.com/article/https://doi.org/10.1007/s00066-015-0884-5.
Potharaju, M. et al. Physique mass index as a prognostic marker in glioblastoma multiforme: A medical consequence. Int. J. Radiat. Oncol. Biol. Phys. 102, 204–209 (2018).
Cano-Gamez, E. & Trynka, G. From GWAS to operate: Utilizing useful genomics to establish the mechanisms underlying complicated illnesses. Entrance. Genet. https://doi.org/10.3389/fgene.2020.00424 (2020).
Li, C. et al. Glucose metabolism-related gene polymorphisms as the chance predictors of kind 2 diabetes. Diabetol. Metab. Syndr. 12, 97 (2020).
Gustafson, B., Hedjazifar, S., Gogg, S., Hammarstedt, A. & Smith, U. Insulin resistance and impaired adipogenesis. Developments Endocrinol. Metab. 26, 193–200 (2015).
Syafruddin, S. E., Nazarie, W. F. W. M., Moidu, N. A., Quickly, B. H. & Mohtar, M. A. Integration of RNA-Seq and proteomics knowledge identifies glioblastoma multiforme surfaceome signature. BMC Most cancers 21, 850 (2021).
Vadakedath, S., Kandi, V., Pinnelli, V. B. Ok. & Godishala, V. A evaluation of signaling pathways and the genetics concerned within the improvement of kind 2 diabetes: Investigating the potential for a vaccine and therapeutic interventions to forestall diabetes. Am. J. Clin. Med. Res. 6, 24–34 (2018).
The therapeutic potential of inhibiting PPARγ phosphorylation to deal with kind 2 diabetes – ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0021925821008322.
Robertson, R., Zhou, H., Zhang, T. & Harmon, J. S. Power oxidative stress as a mechanism for glucose toxicity of the beta cell in kind 2 diabetes. Cell Biochem. Biophys. 48, 139–146 (2007).
Barone, B. B. et al. Lengthy-term all-cause mortality in most cancers sufferers with preexisting diabetes mellitus: A scientific evaluation and meta-analysis. JAMA 300, 2754–2764 (2008).
Hua, H., Kong, Q., Yin, J., Zhang, J. & Jiang, Y. Insulin-like progress issue receptor signaling in tumorigenesis and drug resistance: A problem for most cancers remedy. J. Hematol. Oncol. 13, 64 (2020).
Nigam, M. et al. Analysis of the affiliation of persistent irritation and most cancers: Insights and implications. Biomed. Pharmacother. 164, 115015 (2023).
